Welcome to our dedicated page for Opko Health news (Ticker: OPK), a resource for investors and traders seeking the latest updates and insights on Opko Health stock.
OPKO Health reports developments across a multinational biopharmaceutical and diagnostics business. Recurring updates cover operating results, financial guidance, BioReference laboratory testing services and digital access through BioReference Direct, and RAYALDEE commercialization through EirGen Pharma in Greater China.
The company also reports research collaborations and clinical development from ModeX Therapeutics, including its MSTAR multispecific antibody platform, MDX2301 for COVID-19 prevention, and MDX2003, a tetraspecific T-cell engager for B-cell lymphomas. News also includes pharmaceutical partnerships, diagnostic-service changes, investor presentations, and business updates tied to OPKO's pharmaceutical and diagnostics segments.
Summary not available.
Summary not available.
Summary not available.
OPKO Health, Inc. (NASDAQ: OPK) will announce its financial results for the first quarter of 2023 on May 3, 2023, after market close. The company plans to host a conference call and webcast to discuss the results and provide financial guidance at 4:30 p.m. Eastern time on the same day. Interested participants are encouraged to pre-register for the call to receive a unique PIN for immediate access. A replay of the call will be available until May 10, 2023. OPKO is focused on establishing leading positions in biopharmaceuticals and diagnostics through its proprietary technologies and expertise.
OPKO Health, Inc. (NASDAQ: OPK) has announced an R&D Day event scheduled for March 20, 2023, at 4:00 p.m. Eastern time. This two-hour virtual event will feature presentations from OPKO executives regarding ModeX Therapeutics' multispecific technology platforms, focusing on oncology and infectious diseases. Management will also discuss the MDX-2201 technology associated with a recently announced collaboration with Merck for a vaccine targeting Epstein-Barr virus. Attendees can access the live and archived webcast on OPKO’s Investor Relations website and participate in a Q&A session afterward.
OPKO Health announced an exclusive worldwide license and collaboration agreement with Merck for the development of MDX-2201, a preclinical nanoparticle vaccine targeting the Epstein-Barr virus (EBV). This vaccine aims to address the health challenges posed by EBV, including infectious mononucleosis and associated cancers. Under the agreement, OPKO will receive an upfront payment of $50 million and potential milestone payments totaling up to $872.5 million, in addition to royalties on global sales. The collaboration highlights ModeX's innovative multi-targeting approach and Merck's expertise in vaccine development.
OPKO Health, Inc. (NASDAQ: OPK) reported its fourth-quarter financial results for 2022, noting total revenues of $185.4 million, down from $401.3 million in 2021. The operating loss improved to $55.3 million from $63.1 million year-over-year. Significant highlights included revenue growth in pharmaceuticals, with product sales rising to $37.9 million, primarily from NGENLA® and RAYALDEE. However, diagnostics revenue plummeted to $139.4 million due to decreased COVID-19 testing. The net loss was $85.2 million, or $0.11 per share, compared to a net loss of $73.8 million in the prior year. Cash and cash equivalents stood at $153.2 million.
OPKO Health, Inc. (NASDAQ: OPK) is set to report its operating and financial results for the quarter ended December 31, 2022, on February 23, 2023, after U.S. markets close. The company's senior management will hold a conference call at 4:30 p.m. Eastern time to discuss the results and provide financial guidance. Interested participants are encouraged to pre-register for the call to receive immediate access, while a webcast will also be available for online viewing. Additionally, a telephone replay and webcast replay will be accessible until March 2, 2023. OPKO focuses on biopharmaceuticals and diagnostics within rapidly growing markets.
BioReference Health, one of the largest specialty laboratories in the U.S., announced it will offer the CINtec® PLUS Cytology test from Roche Diagnostics, the only FDA-approved dual-stain triage test for HPV-positive patients. The test is available for women aged 30-65 when cytology results are NILM and HR HPV tests are positive. By utilizing dual-stain biomarker technology, the CINtec PLUS Cytology test aims to improve disease detection and clinical outcomes, potentially reducing follow-up visits. The announcement underscores BioReference's commitment to enhancing cervical cancer screening and patient care.
OPKO Health, Inc. (Nasdaq: OPK) will participate in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. The management will conduct one-on-one meetings and present on January 11 at 4:30 p.m. Pacific time. The presentation will be available via live webcast and later for replay on the OPKO Health website. As a multinational biopharmaceutical and diagnostics company, OPKO aims to lead in rapidly growing markets through innovative technologies and development capabilities.